Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number: 001-37625 Voyager Therapeutics, Inc. (Exact name of Registrant as specified in its charter) Delaware 46-3003182 (S ...

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q1 2023 Results Conference Call May 9, 2023 8:30 AM ET Company Participants Pete Pfreundschuh - Chief Financial Officer Dr. Al Sandrock - Chief Executive Officer Dr. Todd Carter - Chief Scientific Officer Conference Call Participants Jay Olson - Oppenheimer Jack Allen - Baird Philip Nadeau - TD Cowen Yanan Zhu - Wells Fargo Laura Chico - Wedbush Joon Lee - Truist Securities Sumant Kulkarni - Canaccord Operator Good morning and welcome to Voyager Therapeutics First Qu ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number: 001-37625 Voyager Therapeutics, Inc. (Exact name of Registrant as specified in its charter) Delaware 46-3003182 ( ...

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2022 Earnings Conference Call March 7, 2023 8:30 AM ET Company Participants Al Sandrock - Chief Executive Officer Todd Carter - Chief Scientific Officer Pete Pfreundschuh - Chief Financial Officer Allen Nunnally - Chief Business Officer Conference Call Participants Jack Allen - Baird Joon Lee - Truist Dane Leone - Raymond James Yun Zhong - BTIG Laura Chico - Wedbush Yanan Zhu - Wells Fargo Jay Olson - Oppenheimer Operator Good morning and welcome to Voyager Therap ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ For the transition period from to Commission File Number: 001-37625 Voyager Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 46-3003182 (State o ...

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q3 2022 Results Conference Call November 8, 2022 8:30 AM ET Company Participants Alfred Sandrock - Chief Executive Officer Peter Pfreundschuh - Chief Financial Officer Todd Carter - Chief Scientific Officer Conference Call Participants Jack Allen - Robert W. Baird Philip Nadeau - Cowen and Company Laura Chico - Wedbush Yung Zhong - BTIG Dane Leone - Raymond James Sumant Kulkarni - Canaccord Genuity Operator Good morning, and welcome to Voyager Therapeutics Third Quar ...

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Julie Burek - Vice President of Finance Dr. Al Sandrock - Chief Financial Officer Dr. Todd Carter - Senior Vice President of Research Conference Call Participants Jack Allen - Baird Divya Rao - Cowen & Company Yung Zhong - BTIG Operator Good day, and welcome to Voyager Therapeutics Second Quarter 2022 Conference Call. All participants are now in a listen-only mode. There will be a question ...

Dated February 18, 2022 © Voyager Therapeutics © Voyager Therapeutics UNLOCKING THE POTENTIAL OF AAV GENE THERAPY Corporate Presentation | February 2022 Forward-Looking Statements This presentation, posted to the Company's website on December 10, 2021, contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "may," "might," "will," "should," "expect," "plan," "anti ...

® Delivering the Next Generation of Gene Therapies Canaccord Genuity Growth Conference Fireside Chat August 12, 2021 Forward-Looking Statements This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "undoubtedly," "project," "intend," "future," "potential," ...

Call Start: 16:30 January 1, 0000 5:07 PM ET Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2020 Earnings Conference Call February 25, 2021 16:30 ET Company Participants Allison Dorval - Chief Financial Officer Andre Turenne - President & Chief Executive Officer Omar Khwaja - Chief Medical Officer & Head of R&D Conference Call Participants Phil Nadeau - Cowen Ken Shields - Wedbush Hannah Latimer - Morgan Stanley Aydin Huseynov - Benchmark Operator Good afternoon, and welcome to the Voyager Therapeutics Fourth ...